1Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
2Department of Convergence IT Engineering, Pohang University of Science and Technology, Pohang, Korea
3Department of Electrical Engineering, Pohang University of Science and Technology, Pohang, Korea
4BK21 FOUR R&E Center for Learning Health Systems, Korea University, Seoul, Korea
Copyright © 2023 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conception or design: D.Y.L., N.K., S.Y.P., J.H.Y., S.M.P., N.H.K. Acquisition, analysis, or interpretation of data: D.Y.L., N.K., J.A.S., J.K., N.H.K., H.J.Y., S.G.K., K.M.C., S.H.B., S.M.P., N.H.K. Drafting the work or revising: D.Y.L., N.K., I.J.
Final approval of the manuscript: S.M.P., N.H.K.
FUNDING
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) (NRF-2019M3E5D3073102 and NRF-2019R1H1A 2039682), a National IT Industry Promotion Agency (NIPA) grant (No. S0252-21-1001, Development of AI Precision Medical Solution (Doctor Answer 2.0), the Basic Science Research Program through NRF funded by the Ministry of Education (NRF-2020R1I1A1A01071665) funded by the Korean government (MSIT), and a grant (Da Young Lee, 2019F-7) from the Korean Diabetes Association). However, the funders did not participate in the study design or reporting.
Characteristic | All participants (n=122) |
---|---|
Age, yr | 53.4±12 |
Male sex | 65 (53.3) |
BMI, kg/m2 | 27.1±4.5 |
Systolic BP, mm Hg | 131.3±16.0 |
Glycosylated hemoglobin, % | 8.1±1.2 |
Fasting/PP2 glucose, mg/dL | 118.2±36.2/174.5±59.7 |
FCGR/PCGR2 | 0.9±0.8/1.6±1.2 |
Triglyceride, mg/dL | 121.6±61.1 |
HDL-C, mg/dL | 49.0±13.3 |
LDL-C, mg/dL | 68.8±29.9 |
eGFR, mL/min/1.73 m2 | 90.1±24.3 |
Urine ACR, mg/g | 312.1±720.3 |
Urine ACR ≥30 mg/g | 56 (45.9) |
Current drinker | 61 (50) |
Current smoker | 38 (31.2) |
Regular exercise | 55 (45.1) |
Duration of diabetes, yr | 16±10.2 |
Hypertension | 82 (67.2) |
Dyslipidemia | 101 (82.8) |
Stroke | 6 (4.9) |
Ischemic heart disease | 15 (12.3) |
Anti-diabetic drug | |
Basal insulin | |
Glargine | 35 (28.7) |
Degludec | 87 (71.3) |
Total daily dose, U | 29.1±16 |
Prandial insulin | |
Aspart | 75 (61.5) |
Glulisine | 4 (3.3) |
Total daily dose, U | 12.6±15.3 |
Times of injection, /day | |
0 | 43 (35.3) |
1 | 20 (16.4) |
2 | 35 (28.7) |
3 | 23 (18.9) |
Metformin | 116 (95.1) |
Sulfonylurea or meglitinide | 23 (18.9) |
DPP-4 inhibitor | 57 (46.7) |
SGLT-2 inhibitors | 31 (25.4) |
GLP-1 receptor agonist | 5 (4.1) |
Thiazolidinedione | 3 (2.5) |
α-Glucosidase inhibitor | 2 (1.6) |
Fitbit | |
Sleep duration per night, min | 402.9±62.5 |
Energy consumption, kcal/day | 2,283.9±561.9 |
Daily step count | 10,011.5±10,275.0 |
Daytime | 7,324.6±3,947.6 |
Bedtime | 1,020.7±1,107.7 |
Information from the dietary record | |
Calorie intake, kcal/day | 2,061.2±465.4 |
Carbohydrate intake, g/1,000 kcal/day | 131.6±18.3 |
Fat intake, g/1,000 kcal/day | 30.9±6.5 |
Protein intake, g/1,000 kcal/day | 42.8±5.4 |
Fiber intake, g/1,000 kcal/day | 14.8±4.3 |
CGM metrics | |
Time of active CGM, % | 94.0±8.1 |
TIR70‒180 mg/dL, % | 62.8±20.7 |
>70%a | 52 (42.6) |
TAR>250 mg/dL, % | 11.1±12.8 |
<5%a | 57 (46.7) |
TAR>180 mg/dL, % | 35.8±21.0 |
<25%a | 47 (38.5) |
TBR<70 mg/dL, % | 1.3±3.7 |
<4%a | 111 |
TBR<54 mg/dL, % | 0.2±0.9 |
<1%a | 114 |
SD, mg/dL | 51.6±14.2 |
CV, % | 30.7±6.0 |
≤36a | 103 (84.4) |
Values are presented as mean±standard deviation or number of subjects (%).
BMI, body mass index; BP, blood pressure; PP2, 2-hour postprandial; FCGR, fasting C-peptide-to-glucose ratio; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; DPP-4, dipeptidyl peptidase 4; SGLT-2, sodium glucose cotransporter 2; GLP-1, glucagon like peptide-1; CGM, continuous glucose monitoring; TIR, time in range; TAR, time above range; TBR, time below range; SD, standard deviation; CV, coefficient of variation.
a Number and % of those that meet the specified proportions of TAR, TIR, TBR, and CV.
Variable | TIR70‒180 | TAR>250 | TBR<70 | SD | CV |
---|---|---|---|---|---|
Age, yr | –0.11 | 0.15 | –0.01 | 0.20e | 0.15 |
BMI, kg/m2 | –0.24f | 0.20e | –0.27f | 0.09 | –0.08 |
Glycosylated hemoglobin, %a | –0.53g | 0.56g | –0.26f | 0.58g | 0.31f |
Duration of diabetes, yr | –0.22e | 0.26f | –0.01 | 0.33g | 0.23e |
PCGR2b | 0.22e | –0.29f | –0.24f | –0.43g | –0.45g |
eGFR, mL/min/1.73 m2 | 0.22e | –0.31g | –0.05 | –0.41g | –0.36g |
Urine ACR, mg/g | –0.35g | 0.42g | –0.19e | 0.42g | 0.21e |
Daily sleep duration, minc | 0.02 | –0.05 | –0.04 | –0.07 | –0.02 |
Energy consumption, kcal/day | –0.09 | 0.05 | –0.16 | 0.01 | –0.02 |
Daytime step countsb | 0.05 | –0.03 | –0.14 | –0.04 | –0.07 |
Calorie intake, kcal/dayd | –0.15 | 0.10 | –0.10 | 0.07 | –0.05 |
Carbohydrate intake, g/1,000 kcal/day | –0.09 | 0.14 | 0.02 | 0.16 | 0.11 |
Fat intake, g/1,000 kcal/day | 0.16 | –0.18 | 0.08 | –0.16 | –0.05 |
Protein intake, g/1,000 kcal/day | 0.10 | –0.16 | 0.11 | –0.13 | –0.05 |
Fiber intake, g/1,000 kcal/day | 0.05 | –0.01 | 0.22e | 0.09 | 0.19e |
Total daily dose of insulin | –0.27f | 0.29f | 0.03 | 0.37g | 0.31g |
For analyses, TAR>250, TBR<70, PCGR2, and urine ACR levels, and the daytime step count were log-transformed before the analyses to maintain the normality of the residuals.
TIR, time in range; TAR, time above range; TBR, time below range; SD, standard deviation; CV, coefficient of variation; BMI, body mass index; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio.
a Per 0.1 of glycosylated hemoglobin,
b Per 0.1 of LnPCGR2 and Ln (daytime step counts/100),
c Per 10 minutes of daily sleep duration,
d Per 100 kcal of daily calorie intake,
e P<0.05,
f P<0.01,
g P<0.001.
Variable | Odds ratio (95% CI) |
---|---|
Clinical and behavioral factors | f |
Age, yr | 0.98 (0.92‒1.04) |
Male sex | 0.24 (0.09‒0.65) |
BMI, kg/m2 | 0.93 (0.82‒1.05) |
Glycosylated hemoglobin, %b | 0.95 (0.90‒0.99) |
Duration of diabetes, yr | 0.99 (0.92‒1.06) |
PCGR2c | 1.34 (1.03‒1.25) |
eGFR, mL/min/1.73 m2 | 1.01 (0.98‒1.04) |
Urine ACR ≥30 mg/g | 0.32 (0.10‒1.02) |
Daily sleep duration, mind | 0.99 (0.92‒1.08) |
Daytime step countsc | 1.15 (1.03‒1.29) |
Medications and nutritional factors | g |
Sulfonylurea or meglitinide | 0.58 (0.15‒2.29) |
DPP-4 inhibitor | 0.95 (0.33‒2.74) |
SGLT-2 inhibitors | 1.19 (0.40‒3.53) |
Total daily dose of insulin | 0.99 (0.96‒1.02) |
2 or 3 times of prandial insulin per day | 1.37 (0.49‒3.82) |
Calorie intake, kcal/daye | 1.03 (0.91‒1.17) |
Carbohydrate intake, g/1,000 kcal/day | 0.99 (0.96‒1.01) |
Fat intake, g/1,000 kcal/day | 1.02 (0.94‒1.11) |
Protein intake, g/1,000 kcal/day | 0.92 (0.83‒1.02) |
Fiber intake, g/1,000 kcal/day | 0.91 (0.79‒1.06) |
CI, confidence interval; BMI, body mass index; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; DPP-4, dipeptidyl peptidase 4; SGLT-2, sodium glucose cotransporter 2.
a Time in range70‒180 >70%, time above range (TAR)>180 <25%, TAR>250 <5%, time below range (TBR)<70 <4%, TBR<54 <1%, and coefficient of variation ≤36%,
b Per 0.1 of glycosylated hemoglobin (HbA1c),
c Per 0.1 of LnPCGR2 and Ln (daytime step counts/100),
d Per 10 minutes of daily sleep duration,
e Per 100 kcal of daily calorie intake,
f Each variable was adjusted for the other variables in the table,
g gAge, sex, BMI, eGFR, HbA1c, duration of diabetes, PCGR2, urine ACR ≥30 mg/g, daily sleep duration, and daytime step counts were adjusted for each logistic regression analysis.
Variable | No | Yes | P valuea | P valueb |
---|---|---|---|---|
Snack consumption | 60 | 31 | ||
TIR70‒180, % | 62.8±2.3 | 73±3.3 | 0.018 | 0.019 |
TAR>250, % | 7.2 (5.4‒9.5) | 3.9 (2.6‒5.9) | 0.022 | 0.046 |
TBR<70, % | 0.2 (0.0‒0.8) | 0.1 (0.0‒0.6) | 0.470 | 0.382 |
SD, mg/dL | 53.6±1.7 | 44.6±2.5 | 0.006 | 0.007 |
CV, % | 32.1±0.8 | 29±1.1 | 0.028 | 0.086 |
Light bedtime snack | 69 | 22 | ||
TIR70‒180, % | 66.0±2.1 | 67.2±3.8 | 0.792 | 0.866 |
TAR>250, % | 6.2 (4.8‒80) | 4.8 (30‒7.6) | 0.323 | 0.515 |
TBR<70, % | 0.4 (0.0‒1.2) | 0.0 (0.0‒0.2) | 0.002 | 0.006 |
SD, mg/dL | 51.7±1.6 | 46.6±2.8 | 0.119 | 0.305 |
CV, % | 31.7±0.7 | 28.7±1.2 | 0.037 | 0.172 |
Values are presented as least squares mean±standard error or median (interquartile range) after adjustment for age and sex. For analyses, TAR>250, TBR<70 were log-transformed before the analyses to maintain the normality of the residuals.
TIR, time in range; TAR, time above range; TBR, time below range; SD, standard deviation; CV, coefficient of variation.
a P values represent the comparison of two groups using analysis of covariance with adjustment for age and sex,
b P values represent the comparison of two groups using analysis of covariance with adjustment for age, sex, body mass index, estimated glomerular filtration rate, glycosylated hemoglobin, duration of diabetes, 2-hour postprandial C-peptide-to-glucose ratio, urine albumin-to-creatinine ratio ≥30 mg/g, daytime step counts, and daily sleep duration.
Characteristic | All participants (n=122) |
---|---|
Age, yr | 53.4±12 |
Male sex | 65 (53.3) |
BMI, kg/m2 | 27.1±4.5 |
Systolic BP, mm Hg | 131.3±16.0 |
Glycosylated hemoglobin, % | 8.1±1.2 |
Fasting/PP2 glucose, mg/dL | 118.2±36.2/174.5±59.7 |
FCGR/PCGR2 | 0.9±0.8/1.6±1.2 |
Triglyceride, mg/dL | 121.6±61.1 |
HDL-C, mg/dL | 49.0±13.3 |
LDL-C, mg/dL | 68.8±29.9 |
eGFR, mL/min/1.73 m2 | 90.1±24.3 |
Urine ACR, mg/g | 312.1±720.3 |
Urine ACR ≥30 mg/g | 56 (45.9) |
Current drinker | 61 (50) |
Current smoker | 38 (31.2) |
Regular exercise | 55 (45.1) |
Duration of diabetes, yr | 16±10.2 |
Hypertension | 82 (67.2) |
Dyslipidemia | 101 (82.8) |
Stroke | 6 (4.9) |
Ischemic heart disease | 15 (12.3) |
Anti-diabetic drug | |
Basal insulin | |
Glargine | 35 (28.7) |
Degludec | 87 (71.3) |
Total daily dose, U | 29.1±16 |
Prandial insulin | |
Aspart | 75 (61.5) |
Glulisine | 4 (3.3) |
Total daily dose, U | 12.6±15.3 |
Times of injection, /day | |
0 | 43 (35.3) |
1 | 20 (16.4) |
2 | 35 (28.7) |
3 | 23 (18.9) |
Metformin | 116 (95.1) |
Sulfonylurea or meglitinide | 23 (18.9) |
DPP-4 inhibitor | 57 (46.7) |
SGLT-2 inhibitors | 31 (25.4) |
GLP-1 receptor agonist | 5 (4.1) |
Thiazolidinedione | 3 (2.5) |
α-Glucosidase inhibitor | 2 (1.6) |
Fitbit | |
Sleep duration per night, min | 402.9±62.5 |
Energy consumption, kcal/day | 2,283.9±561.9 |
Daily step count | 10,011.5±10,275.0 |
Daytime | 7,324.6±3,947.6 |
Bedtime | 1,020.7±1,107.7 |
Information from the dietary record | |
Calorie intake, kcal/day | 2,061.2±465.4 |
Carbohydrate intake, g/1,000 kcal/day | 131.6±18.3 |
Fat intake, g/1,000 kcal/day | 30.9±6.5 |
Protein intake, g/1,000 kcal/day | 42.8±5.4 |
Fiber intake, g/1,000 kcal/day | 14.8±4.3 |
CGM metrics | |
Time of active CGM, % | 94.0±8.1 |
TIR70‒180 mg/dL, % | 62.8±20.7 |
>70% |
52 (42.6) |
TAR>250 mg/dL, % | 11.1±12.8 |
<5% |
57 (46.7) |
TAR>180 mg/dL, % | 35.8±21.0 |
<25% |
47 (38.5) |
TBR<70 mg/dL, % | 1.3±3.7 |
<4% |
111 |
TBR<54 mg/dL, % | 0.2±0.9 |
<1% |
114 |
SD, mg/dL | 51.6±14.2 |
CV, % | 30.7±6.0 |
≤36 |
103 (84.4) |
Variable | TIR70‒180 | TAR>250 | TBR<70 | SD | CV |
---|---|---|---|---|---|
Age, yr | –0.11 | 0.15 | –0.01 | 0.20 |
0.15 |
BMI, kg/m2 | –0.24 |
0.20 |
–0.27 |
0.09 | –0.08 |
Glycosylated hemoglobin, % |
–0.53 |
0.56 |
–0.26 |
0.58 |
0.31 |
Duration of diabetes, yr | –0.22 |
0.26 |
–0.01 | 0.33 |
0.23 |
PCGR2 |
0.22 |
–0.29 |
–0.24 |
–0.43 |
–0.45 |
eGFR, mL/min/1.73 m2 | 0.22 |
–0.31 |
–0.05 | –0.41 |
–0.36 |
Urine ACR, mg/g | –0.35 |
0.42 |
–0.19 |
0.42 |
0.21 |
Daily sleep duration, min |
0.02 | –0.05 | –0.04 | –0.07 | –0.02 |
Energy consumption, kcal/day | –0.09 | 0.05 | –0.16 | 0.01 | –0.02 |
Daytime step counts |
0.05 | –0.03 | –0.14 | –0.04 | –0.07 |
Calorie intake, kcal/day |
–0.15 | 0.10 | –0.10 | 0.07 | –0.05 |
Carbohydrate intake, g/1,000 kcal/day | –0.09 | 0.14 | 0.02 | 0.16 | 0.11 |
Fat intake, g/1,000 kcal/day | 0.16 | –0.18 | 0.08 | –0.16 | –0.05 |
Protein intake, g/1,000 kcal/day | 0.10 | –0.16 | 0.11 | –0.13 | –0.05 |
Fiber intake, g/1,000 kcal/day | 0.05 | –0.01 | 0.22 |
0.09 | 0.19 |
Total daily dose of insulin | –0.27 |
0.29 |
0.03 | 0.37 |
0.31 |
Variable | Odds ratio (95% CI) |
---|---|
Clinical and behavioral factors | |
Age, yr | 0.98 (0.92‒1.04) |
Male sex | 0.24 (0.09‒0.65) |
BMI, kg/m2 | 0.93 (0.82‒1.05) |
Glycosylated hemoglobin, % |
0.95 (0.90‒0.99) |
Duration of diabetes, yr | 0.99 (0.92‒1.06) |
PCGR2 |
1.34 (1.03‒1.25) |
eGFR, mL/min/1.73 m2 | 1.01 (0.98‒1.04) |
Urine ACR ≥30 mg/g | 0.32 (0.10‒1.02) |
Daily sleep duration, min |
0.99 (0.92‒1.08) |
Daytime step counts |
1.15 (1.03‒1.29) |
Medications and nutritional factors | |
Sulfonylurea or meglitinide | 0.58 (0.15‒2.29) |
DPP-4 inhibitor | 0.95 (0.33‒2.74) |
SGLT-2 inhibitors | 1.19 (0.40‒3.53) |
Total daily dose of insulin | 0.99 (0.96‒1.02) |
2 or 3 times of prandial insulin per day | 1.37 (0.49‒3.82) |
Calorie intake, kcal/day |
1.03 (0.91‒1.17) |
Carbohydrate intake, g/1,000 kcal/day | 0.99 (0.96‒1.01) |
Fat intake, g/1,000 kcal/day | 1.02 (0.94‒1.11) |
Protein intake, g/1,000 kcal/day | 0.92 (0.83‒1.02) |
Fiber intake, g/1,000 kcal/day | 0.91 (0.79‒1.06) |
Variable | No | Yes | P value |
P value |
---|---|---|---|---|
Snack consumption | 60 | 31 | ||
TIR70‒180, % | 62.8±2.3 | 73±3.3 | 0.018 | 0.019 |
TAR>250, % | 7.2 (5.4‒9.5) | 3.9 (2.6‒5.9) | 0.022 | 0.046 |
TBR<70, % | 0.2 (0.0‒0.8) | 0.1 (0.0‒0.6) | 0.470 | 0.382 |
SD, mg/dL | 53.6±1.7 | 44.6±2.5 | 0.006 | 0.007 |
CV, % | 32.1±0.8 | 29±1.1 | 0.028 | 0.086 |
Light bedtime snack | 69 | 22 | ||
TIR70‒180, % | 66.0±2.1 | 67.2±3.8 | 0.792 | 0.866 |
TAR>250, % | 6.2 (4.8‒80) | 4.8 (30‒7.6) | 0.323 | 0.515 |
TBR<70, % | 0.4 (0.0‒1.2) | 0.0 (0.0‒0.2) | 0.002 | 0.006 |
SD, mg/dL | 51.7±1.6 | 46.6±2.8 | 0.119 | 0.305 |
CV, % | 31.7±0.7 | 28.7±1.2 | 0.037 | 0.172 |
Values are presented as mean±standard deviation or number of subjects (%). BMI, body mass index; BP, blood pressure; PP2, 2-hour postprandial; FCGR, fasting C-peptide-to-glucose ratio; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; DPP-4, dipeptidyl peptidase 4; SGLT-2, sodium glucose cotransporter 2; GLP-1, glucagon like peptide-1; CGM, continuous glucose monitoring; TIR, time in range; TAR, time above range; TBR, time below range; SD, standard deviation; CV, coefficient of variation. Number and % of those that meet the specified proportions of TAR, TIR, TBR, and CV.
For analyses, TAR>250, TBR<70, PCGR2, and urine ACR levels, and the daytime step count were log-transformed before the analyses to maintain the normality of the residuals. TIR, time in range; TAR, time above range; TBR, time below range; SD, standard deviation; CV, coefficient of variation; BMI, body mass index; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio. Per 0.1 of glycosylated hemoglobin, Per 0.1 of LnPCGR2 and Ln (daytime step counts/100), Per 10 minutes of daily sleep duration, Per 100 kcal of daily calorie intake, P<0.05, P<0.01, P<0.001.
CI, confidence interval; BMI, body mass index; PCGR2, 2-hour postprandial C-peptide-to-glucose ratio; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; DPP-4, dipeptidyl peptidase 4; SGLT-2, sodium glucose cotransporter 2. Time in range70‒180 >70%, time above range (TAR)>180 <25%, TAR>250 <5%, time below range (TBR)<70 <4%, TBR<54 <1%, and coefficient of variation ≤36%, Per 0.1 of glycosylated hemoglobin (HbA1c), Per 0.1 of LnPCGR2 and Ln (daytime step counts/100), Per 10 minutes of daily sleep duration, Per 100 kcal of daily calorie intake, Each variable was adjusted for the other variables in the table, gAge, sex, BMI, eGFR, HbA1c, duration of diabetes, PCGR2, urine ACR ≥30 mg/g, daily sleep duration, and daytime step counts were adjusted for each logistic regression analysis.
Values are presented as least squares mean±standard error or median (interquartile range) after adjustment for age and sex. For analyses, TAR>250, TBR<70 were log-transformed before the analyses to maintain the normality of the residuals. TIR, time in range; TAR, time above range; TBR, time below range; SD, standard deviation; CV, coefficient of variation.